CHDI Foundation, privately funded by a small group of anonymous donors started work on Huntington's disease (HD) about a decade ago. Many have wondered what criteria this organization would require to launch a new drug into clinical trial. The PDE10A inhibitor story answers that question and shows the careful and powerful process that CHDI utilizes before promoting a drug candidate to clinical trial. "Aligning the stars" has nothing to do with serendipity or luck. It is about a lot of hard work, with the CHDI role that of "collaborative enabler" with financial clout: to guide, support, and coordinate a multitude of scientists and drug developers.
Get your telescope ready: The stars are being moved into place...
Treatment Guidelines for Huntington's: Who needs them?
Posted by LaVonne Goodman M.D.
During my years as an internal medicine physician, I have used standard of care guidelines for my patients with conditions like diabetes and heart disease. Guidelines are developed by experts in each disease who
translate clinical trial evidence and/or expert experience into recommended care patterns
for use in medical offices or at the bedside. When followed, guidelines have been central to improving the
quality of care provided by all physicians whether they are specialists or
generalists.
